Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 29;2(3):624-41.
doi: 10.3390/vaccines2030624.

Developments in Viral Vector-Based Vaccines

Takehiro Ura  1 , Kenji Okuda  1 , Masaru Shimada  2
Affiliations
Review

Developments in Viral Vector-Based Vaccines

Takehiro Ura et al. Vaccines (Basel). .

Abstract

Viral vectors are promising tools for gene therapy and vaccines. Viral vector-based vaccines can enhance immunogenicity without an adjuvant and induce a robust cytotoxic T lymphocyte (CTL) response to eliminate virus-infected cells. During the last several decades, many types of viruses have been developed as vaccine vectors. Each has unique features and parental virus-related risks. In addition, genetically altered vectors have been developed to improve efficacy and safety, reduce administration dose, and enable large-scale manufacturing. To date, both successful and unsuccessful results have been reported in clinical trials. These trials provide important information on factors such as toxicity, administration dose tolerated, and optimized vaccination strategy. This review highlights major viral vectors that are the best candidates for clinical use.

Keywords: CTL; MVA; adenovirus; vaccine; viral vector.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jackson D.A., Symons R.H., Berg P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc. Natl. Acad. Sci. USA. 1972;69:2904–2909. doi: 10.1073/pnas.69.10.2904. - DOI - PMC - PubMed
    1. Mackett M., Smith G.L., Moss B. Vaccinia virus: A selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. Sci. USA. 1982;79:7415–7419. doi: 10.1073/pnas.79.23.7415. - DOI - PMC - PubMed
    1. Panicali D., Paoletti E. Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl. Acad. Sci. USA. 1982;79:4927–4931. doi: 10.1073/pnas.79.16.4927. - DOI - PMC - PubMed
    1. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801. doi: 10.1016/j.cell.2006.02.015. - DOI - PubMed
    1. Guideline on quality, non-clinical and clinical aspects of live recombinant viral vectored vaccines. [(accessed on June 24, 2009)]. Available online: http://www.google.co.jp/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CB....